Physician profile
Jesse Baker
NPI 1417405291
$1,478.32
in general payments reported to CMS, 2019-2025
19 companies · $56.44 in 2025
The $56.44 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $274 · 2023: $501 · 2024: $647 · 2025: $56.44.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,204.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,204.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $246.40 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $205.55 | 2022-2025 | Wegovy, Rybelsus, Ozempic |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $196.63 | 2022-2024 | Xifaxan |
| Glaxosmithkline, LLC. | $132.85 | 2023-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Sanofi-Aventis U.S. LLC | $115.85 | 2022-2024 | |
| Merck Sharp & Dohme LLC | $101.68 | 2022-2024 | Gardasil 9, Steglatro, Belsomra |
| Exact Sciences Corporation | $98.14 | 2023-2024 | Cologuard Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $71.78 | 2022-2024 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $69.94 | 2023-2024 | Farxiga, Airsupra |
| Idorsia Pharmaceuticals US INC | $49.20 | 2023-2024 | Quviviq |
| Abbvie INC. | $46.57 | 2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $34.64 | 2024-2025 | |
| Sanofi Pasteur INC. | $21.34 | 2022 | |
| Amgen INC. | $19.85 | 2024 | Repatha, Otezla |
| Amarin Pharma, INC. | $16.37 | 2022 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $15.70 | 2022 | |
| Pfizer INC. | $13.68 | 2023 | |
| Biohaven Pharmaceutical Holding Company LTD. | $12.18 | 2022 | |
| Alpha Cognition USA, INC. | $9.97 | 2025 | Zunveyl |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jesse Baker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.